N-甲氧基-N-甲基异丁酰胺 | 113778-69-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-甲氧基-N-甲基异丁酰胺
• 中文别名: N-甲氧基-N,2-二甲基丙酰胺
• 英文名称: N-methoxy-N-methyl-isobutyramide
• 英文别名: N-methoxy-N,2-dimethylpropanamide
• CAS: 113778-69-1
• 化学式: C₆H₁₃NO₂
• mdl: MFCD11847606
• 分子量: 131.175
• InChiKey: HAWUPFPGLDIOFA-UHFFFAOYSA-N

物化性质

• 沸点：
  137.7±23.0 °C(Predicted)
• 密度：
  0.945±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、DCM、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methoxy-N,2-dimethylpropanamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methoxy-N,2-dimethylpropanamide
CAS number: 113778-69-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13NO2
Molecular weight: 131.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲氧基-N-甲基异丁酰胺 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.5h， 生成 2-(1-甲基乙基)-1H-吡咯并[2,3-b]吡啶
  参考文献：
  名称：

  WO2008/145688

  摘要：

  公开号：
• 作为产物：
  描述：

  异丁酸 、 N-甲基-N-甲氧基胺盐酸盐 在 三氯化磷 作用下， 以 甲苯 为溶剂， 反应 0.67h， 以95%的产率得到N-甲氧基-N-甲基异丁酰胺
  参考文献：
  名称：

  直接由羧酸直接一锅无过渡金属合成Weinreb酰胺

  摘要：

  摘要 在一个锅中于60°C在甲苯中以高收率直接由羧酸，N，O-二甲基羟胺和三氯化磷直接制备Weinreb酰胺，从而避免了对水分和空气敏感的中间体P [NMe（OMe）] 3的分离。提前。受位阻的羧酸也以优异的产率得到相应的Weinreb酰胺。羧酸上具有各种官能团。该方法工艺简单，收率高，适合大规模生产。 在一个锅中于60°C在甲苯中以高收率直接由羧酸，N，O-二甲基羟胺和三氯化磷直接制备Weinreb酰胺，从而避免了对水分和空气敏感的中间体P [NMe（OMe）] 3的分离。提前。受位阻的羧酸也以优异的产率得到相应的Weinreb酰胺。羧酸上具有各种官能团。该方法工艺简单，收率高，适合大规模生产。

  DOI：

  10.1055/s-0033-1340317

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047959A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量、空腹血糖升高、2型糖尿病、综合征X（也称为代谢综合征）及其相关疾病和并发症。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047961A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量，空腹血糖升高，2型糖尿病，综合征X（也称为代谢综合征）以及与之相关的疾病和并发症。